TFF Pharmaceuticals, which develops dry powder inhalation products based on its thin film freezing technology, has announced that Glenn Mattes will step down as CEO and that he will be succeeded on an interim basis by Harlan F. Weisman. Mattes joined TFF in 2018. Weisman’s experience includes a number of leadership roles at Johnson & Johnson, Centocor, Coronado Biosciences, and Flame Biosciences. He is currently Vice Chairman of TFF’s board and Managing Director of And-One Consulting.
TFF recently announced the expansion of its R&D center in Austin, TX, USA. The company’s pipeline includes includes inhaled formulations of niclosamide for COVID-19; Aug-3387 mAb for COVID-19; voriconazole for IPA; tacrolimus for prevention of organ transplant rejection; dry powder vaccines, including nasal dry powder vaccines, and an inhaled mAb against Ebola.
Mattes said, “I would like to thank the dedicated employees of TFF Pharmaceuticals for having the opportunity and privilege to work with all of you over the last five years on a truly unique and innovative technology that could have a great impact on many patients. I am confident that under Harlan’s leadership, this mission will continue, and I look forward to helping the board in any way during this transition period for the company.”
Weisman commented, “I am honored to serve as Interim Chief Executive Officer of TFF Pharmaceuticals, and I would like to thank our board of directors for this opportunity. Based upon the company’s significant pipeline growth and impressive collaboration activity, I remain confident that we are only starting to realize the full therapeutic and commercial potential of thin film freezing technology.”
Read the TFF Pharmaceuticals press release.
